Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · colon-landscapes@1

SRR12475107

—

b716149f-ef56-5715-b1d3-8cd6cd96b406

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.320
  • DNA_REPAIR+0.300
  • G2M_CHECKPOINT+0.260
  • E2F_TARGETS+0.240
  • MYC_TARGETS_V1+0.190
  • WNT_BETA_CATENIN_SIGNALING+0.190
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.160
  • CHOLESTEROL_HOMEOSTASIS+0.080
  • OXIDATIVE_PHOSPHORYLATION+0.080
  • GLYCOLYSIS+0.070

Top 10 suppressed

  • ALLOGRAFT_REJECTION-0.410
  • INTERFERON_GAMMA_RESPONSE-0.400
  • INTERFERON_ALPHA_RESPONSE-0.380
  • HEDGEHOG_SIGNALING-0.360
  • INFLAMMATORY_RESPONSE-0.360
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
  • IL6_JAK_STAT3_SIGNALING-0.320
  • ANDROGEN_RESPONSE-0.310
  • ANGIOGENESIS-0.310
  • COMPLEMENT-0.310

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
163bab58e-1dfd-43df-8188-4b8d766913f3
colon-landscapes@1
——0.880
2GSM6454731
breast-umap@18
—E0.880
3cf37eb41-0595-4a82-a65b-3058902a48d4
colon-landscapes@1
——0.877
4SRR8518240
breast-umap@18
—E0.864
5TCGA-AN-A04D-01A-21R-A034-07
breast-umap@18
—E0.860
64db3046e-1628-4cd7-a362-d169176d9fd8
colon-landscapes@1
——0.857
7BS_53M8PP88
brain-umap@2
Ependymoma NOS—0.854
8TCGA-56-7730-01A-11R-2125-07
lung-landscapes@6
—cohortSQ20.854
9MDT-AP-0421
medullo-epn-umap@date-based
MedMedulloblastoma0.853
10MDT-AP-1199
medullo-epn-umap@date-based
MedMedulloblastoma0.853

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 15 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.320Idelalisib— uncovered
DNA_REPAIR0.300Idelalisib— uncovered
G2M_CHECKPOINT0.260Inavolisib— uncovered
E2F_TARGETS0.240Inavolisib— uncovered
MYC_TARGETS_V10.190Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.190Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.160Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.080Remibrutinib— uncovered
OXIDATIVE_PHOSPHORYLATION0.080Remibrutinib— uncovered
GLYCOLYSIS0.070Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.060Inavolisib— uncovered
PEROXISOME0.050Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.050Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.040Inavolisib— uncovered
UV_RESPONSE_UP0.030Idelalisib— uncovered